透過您的圖書館登入
IP:18.116.42.208

摘要


前言:Glypican-3已經在不同類型的腫瘤中被發現。然而,關於Glypican-3在乳癌的角色的資訊仍然非常有限。組織微陣列使用對原始組織標本最小損害的平行原點塊來分析數以千計的標本。本研究將使用組織微陣列檢測乳癌中的Glypican-3之表現。材料方法:以組織微陣列的組織免疫染色來分析99個原發浸潤性乳腺癌案例的組織檢體的Glypican-3之表現。結果將與臨床病理資料多元分析及比較。結果:TNM分期顯著與5年內的生存率相關。不過,Glypican-3的表現與5年內的生存率沒有明顯的關係。結論:組織微陣列的組織免疫染色是方便及適合用於分析乳癌中的Glypican-3。我們的初步結果顯示,Glypican-3的表現在乳腺癌無顯著預後價值。

關鍵字

乳癌 組織微陣列

並列摘要


Background: The protein Glypican-3 has been found in various types of tumors and has shown promise as a tumor marker. However, there is still very limited information about the role of Glypican-3 in breast cancer. Tissue microarray (TMA) analyzes thousands of specimens in parallel with minimal damage to the origin blocks. The purpose of this study was to ascertain the role of Glypican-3 status in breast cancer using TMA. Materials and Methods: Archival tissue specimens from 99 patients with primary invasive breast cancer were analyzed for Glypican-3 expression by immunohistochemical staining with TMA. The results were compared to clinicopathologic data by the use of multivariate analysis. Results: TNM stage was significantly related to the overall 5-year survival rate. Nevertheless, Glypican-3 expression has no significant relationship to overall five-year survival. Conclusions: Immunohistochemical staining with TMA was convenient and feasible for analyzing Glypican-3 expression status in breast cancer. However, our preliminary results show that Glypican-3 expression had no significant prognostic value in breast cancer.

並列關鍵字

glypican-3 breast cancer tissue microarray

延伸閱讀